Eisai Inc., of Woodcliff Lake, N.J., said the FDA approved the company's receptor tyrosine kinase inhibitor Lenvima (lenvatinib) for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.